FORMULATION AND IN VITRO EVALUATION OF BILAYERED …

Proton Pump Inhibitors (PPI): The Proton Pump Inhibitor therapeutic class ranked 3rd in Medicaid pharmacy program by total cost of drug claims in calendar year 2009. In addition, there is increasing evidence that long-term use of PPIs may be associated with increased risks to the patient, such as increased rate of spine, lower arm, and total ... ................
................